LPCN Lipocine Inc.

3.69
0  0%
Previous Close 3.70
Open 3.70
Price To book 2.62
Market Cap 68.61M
Shares 18,594,000
Volume 105,855
Short Ratio 9.48
Av. Daily Volume 130,600

SEC filingsSee all SEC filings

  1. 8-K - Current report 17736204
  2. 8-K - Current report 17683956
  3. 424B5 - Prospectus (Rule 424(b)(5)) 17667930
  4. 8-K - Current report 17667906
  5. 8-K - Current report 17667863

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b top-line data released September 2016. End of Phase 2 meeting with FDA anticipated for 2H 2017.
LPCN 1111
Oral testosterone product
CRL issued June 2016. Dosing flexibility trial to be initiated 1Q 2017 with data due in 2Q 2017.
LPCN 1021
Men with low testosterone (Low T)
Phase 3 protocol to be filed with FDA 1H 2017.
LPCN 1107
Prevention of preterm birth ("PTB").

SEC Filings

  1. 8-K - Current report 17736204
  2. 8-K - Current report 17683956
  3. 424B5 - Prospectus (Rule 424(b)(5)) 17667930
  4. 8-K - Current report 17667906
  5. 8-K - Current report 17667863
  6. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17667848
  7. 8-K - Current report 17612932
  8. SC 13G/A (Amend) - Statement of acquisition of beneficial ownership by individuals 17612217
  9. SC 13G/A (Amend) - Statement of acquisition of beneficial ownership by individuals 17581991
  10. 8-K - Current report 17560307